Oklo CEO on nuclear growth strategy: 'We're in full build mode'

from. >> CNBC. Cures Defying Rare Disease premieres Thursday >> WELCOME BACK TO MONEY MOVERS.REPORTING FULL YEAR RESULTS FOR 25, A LOSS PER SHARE OF $0.72%, A LITTLE BETTER THAN EXPECTED. COMPANY ALSO ANNOUNCED IT'S RECEIVED ITS FIRST EVER LICENSE FROM THE NUCLEAR REGULATORY COMMISSION VIA A SUBSIDIARY, WHICH WILL ALLOW THE COMPANY TO SELL SOME ISOTOPE MATERIALS. JOINING US EXCLUSIVELY FROM THE COMPANY'S ISOTOPES TEST REACTOR NEAR LOCKHART, TEXAS, IS CEO JACOB DEWITT.JACOB, ALWAYS GOOD TO HAVE YOU. THANKS F ...